Table 2.
Results from univariate cox regression analysis of whether one group had a significantly (p < 0.05) higher chance of treatment failure than another group with an associated HR
| Group | HR | P | |
| T stage | T4 | 0.9 | 0.9 |
| T3-4 | 1.3 | 0.7 | |
| N stage | N3 | 8.0 | 0.001 |
| N1-3 | 8.2 | 0.05 | |
| Gender | male | 2.0 | 0.3 |
| Weight * | >86 kg | 0.9 | 0.8 |
| Age * | >70 years | 1.0 | 1.0 |
| HPV | negative | 5.9 | 0.005 |
| SUVmax * | >13 | 2.2 | 0.2 |
| SUVpeak * | >8 | 1.4 | 0.6 |
| SUVmean * | >6 | 0.8 | 0.8 |
| Tumor ø * | >6 cm | 3.9 | 0.02 |
| GTV * | >178 | 5.0 | 0.008 |
| MTV * | >23 | 5.2 | 0.007 |
| TLG * | >259 | 5.2 | 0.007 |
| ZMP * | >0.54 | 5.3 | 0.006 |
GTV, gross tumor volume; HPV, human papilloma virus; HR, hazard ratio; MTV, metabolic tumor volume; SUV, standardized uptake value; TLG, total lesion glycolysis.
*
Group divisions were created by separating the 20% highest values from the 80% lowest values.